TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07517198: Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$6,251,784

Rescue Site Savings

+$4,115,496

Unlock Full NCT07517198 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07517198 Rescue Dossier →